To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over these assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic ...

Essex Management, an Emmes Group company, has appointed David Loose as Chief Executive Officer (CEO), effective immediately.

The companies entered the agreement in 2023 to jointly advance as many as 11 drug programs, mainly targeting cardiovascular ...

Increases speed to market for drug developers working on nucleic acid therapeutics.

Mytos, a provider of automated cell manufacturing, has entered a manufacturing collaboration with Aspen Neuroscience, Inc. to ...

Mytos has entered into a manufacturing collaboration with Aspen Neuroscience Inc. to automate the manufacturing of autologous ...

Antag Therapeutics, a biopharmaceutical company pioneering novel treatments for obesity, has appointed Joerg Moeller, MD, PhD ...

NorthStar Medical Radioisotopes, LLC and YAP Therapeutics, Inc. have formed a partnership to develop and manufacture ...